Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy
Joint Authors
Jimbow, Kowichi
Ito, Akira
Ono, Ichiro
Ito, Shosuke
Honda, Hiroyuki
Yamashita, Toshiharu
Sato, Makito
Sato, Akiko
Takada, Tomoaki
Miyamoto, Atsushi
Sato, Noriyuki
Wakamatsu, Kazumasa
Tamura, Yasuaki
Source
Issue
Vol. 2009, Issue 2009 (31 Dec. 2009), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2009-09-07
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals.
Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF).
This study tested if a chemo-thermo-immunotherapy (CTI therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles (NPrCAP/M).
We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth.
The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant.
The heat-generated therapeutic effect was more significant at a temperature of 43∘C than either 41∘C or 46∘C.
NPrCAP/M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice.
HSP70 production was greatest at 43∘C compared to that with 41∘C or 46∘C.
CD8+T cells were infiltrated at the site of the re-challenge melanoma transplant.
American Psychological Association (APA)
Takada, Tomoaki& Yamashita, Toshiharu& Sato, Makito& Sato, Akiko& Ono, Ichiro& Tamura, Yasuaki…[et al.]. 2009. Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy. BioMed Research International،Vol. 2009, no. 2009, pp.1-13.
https://search.emarefa.net/detail/BIM-988375
Modern Language Association (MLA)
Takada, Tomoaki…[et al.]. Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy. BioMed Research International No. 2009 (2009), pp.1-13.
https://search.emarefa.net/detail/BIM-988375
American Medical Association (AMA)
Takada, Tomoaki& Yamashita, Toshiharu& Sato, Makito& Sato, Akiko& Ono, Ichiro& Tamura, Yasuaki…[et al.]. Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy. BioMed Research International. 2009. Vol. 2009, no. 2009, pp.1-13.
https://search.emarefa.net/detail/BIM-988375
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-988375